One of these RTKs, known as c-Met, as well as the proto-oncogene cytoplasmic tyrosine kinase Src, and its substrates p130Cas were found to be down-regulated in prostate cancer cells that express KAI1 (Sridhar and Miranti, 2006). Here, CD82 is linked to prostate cancer.